Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Neuromodulation to Facilitate the Effect of Ketamine

NCT01816958 · View on ClinicalTrials.gov ↗

Study Summary

application of external neuromodulation along with ketamine infusion.

Interventions

  • OTHER co-administration of TMS and infused ketamine

Study Locations (1)

Illinois

  • The Neuroscience Center — Deerfield

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2011-01
Est. Completion 2012-11

Sponsor

The Neuroscience Center

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01816958

The ClinicalTrials.gov registry entry for NCT01816958 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Neuroscience Center, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention — of which co-administration of TMS and infused ketamine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01816958 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01816958 about?

NCT01816958 is a clinical study titled "Neuromodulation to Facilitate the Effect of Ketamine". application of external neuromodulation along with ketamine infusion.

What is the current status of trial NCT01816958?

This trial is currently completed. The enrollment target is 35 participants. The study started on 2011-01. Estimated completion is 2012-11.

What conditions does trial NCT01816958 study?

This clinical trial studies the following conditions: Depression, Chronic Pain, Substance Abuse. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01816958?

The interventions under investigation include: co-administration of TMS and infused ketamine (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01816958?

This trial is sponsored by The Neuroscience Center, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01816958 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial